Oncotarget

Research Papers:

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells

Sheng Tai, Lingfan Xu, Ming Xu, Ligang Zhang, Yangyang Zhang, Kaipin Zhang, Li Zhang and Chaozhao Liang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:11206-11218. https://doi.org/10.18632/oncotarget.14493

Metrics: PDF 2225 views  |   HTML 2789 views  |   ?  


Abstract

Sheng Tai1,2, Lingfan Xu1,2, Ming Xu1,2, Ligang Zhang1,2, Yangyang Zhang1,2, Kaipin Zhang1,2, Li Zhang1,2, Chaozhao Liang1,2

1The Department of Urology, The First Affiliated Hospital of Anhui Medical University, China

2The Department of Urology, The Urological Institute of Anhui Medical University, China

Correspondence to:

Sheng Tai, email: [email protected]

Chaozhao Liang, email: [email protected]

Keywords: Rad001, ATO, synergism, autophagy, prostate cancer

Received: August 05, 2016     Accepted: December 27, 2016     Published: January 04, 2017

ABSTRACT

The inhibitor of PI3K-AKT-mTOR pathway, such as Rad001, has not shown therapeutic efficacy as a single agent in prostate cancer. Arsenic trioxide induces the autophagic pathway in prostate cancer cells. We identified Arsenic trioxide can synergize with Rad001 to induce cytotoxicity of prostate cancer cells. Moreover, we identified synergistic induction of autophagy and apoptosis as the underlying mechanism. This enhanced autophagic cell death is accompanied by increased Beclin1 mRNA stability as well as upregulation of ATG5-ATG12 conjugate, Beclin1, and LC3-2. Rad001 and ATO also can synergistically inhibit tumors in prostate cancer xenograft animal model. These results identify and validate a novel mechanism to enhance and expand the existing targeted therapeutic agent to treat prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14493